Abbvie Inc
NYSE:ABBV
Abbvie Inc
NYSE:ABBV
Price:
167.8 USD
-1.03%
Market Closed
Updated:
Apr 25, 2024
Abbvie Inc
Operating Income
Last
Value
3-Years CAGR
5-Years CAGR
|
Abbvie Inc
Operating Income Peer Comparison
Comparables:
GILD
AMGN
VRTX
REGN
SGEN
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$9.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
|
|
Seagen Inc
NASDAQ:SGEN
|
Operating Income
-$750.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-29%
|
See Also
What is Abbvie Inc's Operating Income?
Operating Income
16.6B
USD
16.6B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Operating Income amounts to 16.6B USD.
What is Abbvie Inc's Operating Income growth rate?
Operating Income CAGR 10Y
11%
11%
Over the last year, the Operating Income growth was -18%. The average annual Operating Income growth rates for Abbvie Inc have been 8% over the past three years , 7% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
